Research Status and Future Trends of Targeted Biologics for Severe Asthma
Asthma is a common chronic airway inflammatory disease in the world,and severe asthma is difficult to be well controlled,which is a great challenge in clinical treatment.With the deepening of the research on the mechanism and treatment of severe asthma,targeted biotherapy has become a new therapeutic approach for the treatment of severe asthma.Currently approved biologics mainly include anti-IL-5/IL-5R monoclonal antibodies,anti-IgE monoclonal antibodies,anti-IL-4/13 monoclonal antibodies,anti-TSLP monoclonal antibodies,mainly for patients with severe asthma with predominant type 2 inflammation,and have been shown to be a good alternative to corticosteroids,especially in the management of severe asthma,which can improve the quality of life of many patients.In this article,we reviewed the pathogenesis and targeted biological agents for type 2 inflammatory severe asthma,and addressed the importance of further study on asthma pathogenesis and development of new biological agents,so as to provide reference for clinical rational drug use and future research.
万方数据
维普
